We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Proton Pump Inhibitors and Dementia Incidence

David Louis Keller, MD1
[+] Author Affiliations
1Lomita, California
JAMA Neurol. 2016;73(8):1025. doi:10.1001/jamaneurol.2016.1488.
Text Size: A A A
Published online


To the Editor Dietary aluminum ingestion is theorized to be neurotoxic and play a causative role in the onset and progression of dementia.13 A recent meta-analysis showed that individuals chronically exposed to aluminum were 71% more likely to develop Alzheimer disease (odds ratio, 1.71; 95% CI, 1.35-2.18).4 Many strong antacids contain aluminum hydroxide and are often taken for years by patients with peptic ulcer disease or gastroesophageal reflux before they are prescribed proton pump inhibitors, and concurrent with their use. Gomm and colleagues5 do not correct for the use of aluminum-containing antacids when calculating the association of dementia with proton pump inhibitor use. How much of their observed association of proton pump inhibitor use with dementia is actually due to long-term ingestion of aluminum antacids, either currently or in the past?


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





August 1, 2016
Tomoyuki Kawada, MD
1Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan
JAMA Neurol. 2016;73(8):1025-1026. doi:10.1001/jamaneurol.2016.1491.
August 1, 2016
Helge L. Waldum, MD, PhD; Tom Christian Martinsen, MD, PhD
1Norwegian University of Science and Technology2Department of Gastroenterology and Liver Diseases, St Olavs Hospital, Trondheim, Norway
JAMA Neurol. 2016;73(8):1026. doi:10.1001/jamaneurol.2016.1497.
August 1, 2016
Jineane V. Venci, PharmD, BCACP; Katherine W. Eisenberg, MD, PhD
1University of Rochester Medical Center, Rochester, New York
JAMA Neurol. 2016;73(8):1026. doi:10.1001/jamaneurol.2016.1500.
August 1, 2016
William D. Freeman, MD
1Department of Critical Care, Mayo Clinic, Jacksonville, Florida2Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida3Department of Neurology, Mayo Clinic, Jacksonville, Florida
JAMA Neurol. 2016;73(8):1026-1027. doi:10.1001/jamaneurol.2016.1503.
August 1, 2016
Kanika Sharma, MD; Alireza Minagar, MD; Hai Sun, MD, PhD
1Department of Neurosurgery, Louisiana State University Health Sciences Center, Shreveport
2Department of Neurology, Louisiana State University Health Sciences Center, Shreveport
JAMA Neurol. 2016;73(8):1027. doi:10.1001/jamaneurol.2016.1959.
August 1, 2016
Long Nguyen, MD, MS; Chin Hur, MD, MPH
1Gastroenterology, Massachusetts General Hospital, Boston
JAMA Neurol. 2016;73(8):1027-1028. doi:10.1001/jamaneurol.2016.1962.
August 1, 2016
Willy Gomm, PhD; Britta Haenisch, PhD
1German Center for Neurodegenerative Diseases, Bonn, Germany
JAMA Neurol. 2016;73(8):1028-1029. doi:10.1001/jamaneurol.2016.1494.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment
Cholinesterase Inhibitiors, Memantine and Proton Pump Inhibitors: Was there a relationship seen in the AKO data?
Posted on June 27, 2016
Chew S
Changi General Hospital
Conflict of Interest: None Declared
Dear Sir/Madam,

In the past, cholinesterase and memantine was only considered in the later part of dementia. Of late, they are being started earlier and earlier in the course of the disease. One of the common adverse drug reactions of cholinesterase inhibitors and memantine relate to the gastrointestinal tract. There has also been some case reports of upper gastrointestinal bleeding in patients on treatment with cholinesterase inhibitor although the trial data does not show this association. [1,2]

I wonder if the authors saw any association between the use of proton pump inhibitors and concurrent cholinesterase inhibitors and/or memantine in the data over the course of time, in addition to the relationship of the former with dementia?

I could not find the answer to this querry in the potential confounding factors section of the article.

Thank you.

1. Cholongitas E, Pipili C, Dasenaki M. Recurrence of Upper Gastrointestinal Bleeding After Donepezil Administration. Alzheimer Disease & Associated Disorders. 2006 Oct/Dec;20(4):326

2. Kok KS, Loke Y, Southgate J. Upper gastrointestinal bleed associated with cholinesterase inhibitor use.BMJ Case Rep. 2015 Sep 29;2015.
Response to Dr Chew
Posted on July 18, 2016
Britta Haenisch
Conflict of Interest: None Declared
Dear Dr Chew,
Thank you for your comment. As you mentioned, acetylcholinesterase inhibitors and memantine are often prescribed in late stages of dementia. Furthermore, the majority of dementia patients in Germany did not receive these antidementia drugs in the past years [1]. Thus, concurrent prescription of PPIs and antidementia drugs before a dementia diagnosis was negligible in our data and did not change the results of our study.
[1] van den Bussche H, Kaduszkiewicz H, Koller D, et al. (2011) Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up. Int Clin Psychopharmacol 26: 225-231.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...